22 June 2023 - The US Medicare health plan on Thursday offered details of plans to collect patient data as a condition for reimbursement for Eisai and Biogen's new Alzheimer's drug Leqembi, should it win traditional US approval as expected by July 6.

Under the plan, Medicare, the Government health plan for Americans 65 and older, would require physicians to take part in a data collection effort, known as a patient registry, that would be run by the Centers for Medicare and Medicaid Services.

Read Reuters article